Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal
Everest Medicines Limited (HKG: 1952) announced a licensing agreement with Micot, a polypeptide NME drug...
Deals
MediTrust Mabwell Insurance Ecosystem Partnership
Shanghai MediTrust Health Technology Group Co., Ltd. (a subsidiary of Shanghai Pharmaceuticals) announced a comprehensive...
Pfizer Launches Migraine Management Zone at China Pharmacy
Pfizer Inc. (NYSE: PFE) in collaboration with GuoDa Drugstore Co., Ltd. (part of Sinopharm) this week...
Takeda Ends $128M Kyoto University iPSC Project After Decade of Research
Takeda Pharmaceutical (TYO: 4502, NYSE: TAK) announced the termination of its ten‑year induced pluripotent stem cell (iPSC)...
Mirxes Partners with XtalPi and Signet on AI-Driven Gastric Cancer System
Mirxes Singapore (HKG: 2629) announced a partnership with XtalPi Inc. (QuantumPharm, HKG: 2228) and its...
Lishan Biopharma Licenses Evogene’s LS-LBP-002 for Global Oncology Development
Shanghai Lishan Biopharmaceuticals Co., Ltd. announced a licensing agreement with Israel‑based Evogene Ltd. (NASDAQ: EVGN) for...
Bio-Thera Licenses Keytruda Biosimilar BAT3306 to Avalon for Middle East & North Africa
Bio-Thera Solutions (SHA: 688177) announced a licensing agreement with Avalon Pharma, granting the Saudi Arabia‑headquartered...
Akeso Licenses Yixining to Jumpcan for PCSK9 Promotion in China
Akeso Biopharma (HKG: 9926) announced a partnership with Jumpcan Pharmaceutical (SHA: 600566) granting Jumpcan exclusive...
Grand Pharmaceutical to Acquire API Firms for RMB 316 Million
Grand Pharmaceutical Group Limited (HKG: 0512) announced plans to acquire 100% equity in Hebei Grand...
Simcere Receives $40M Milestone from AbbVie for Trispecific Myeloma Drug
Simcere Pharmaceutical Group Ltd (HKG: 2096) announced it has received a USD 40 million near‑term milestone payment from...
Medtronic to Acquire CathWorks for $585M, Expand AI-Based FFRangio System
Medtronic Inc. (NYSE: MDT) announced it will exercise its option to acquire Israel-based medical device company...
TenNor Therapeutics Files Hong Kong IPO for Anti-Infective Pipeline
TenNor Therapeutics (Suzhou) Limited submitted its initial public offering (IPO) application to the Main Board...
Insilico Medicine Doses First Patient in MEN2501 Phase I, Triggers $5M Menarini Milestone
Insilico Medicine (HKG: 3696) announced the first patient dosing in a Phase I clinical study...
PrimeGenX Therapeutics Files Hong Kong IPO for Pumecitinib Platform
PrimeGenX Therapeutics Co., Ltd., a Beijing‑based immuno‑inflammation biotech founded in 2016, made an initial public...
Jumpcan Licenses PrimeGenX Pumecitinib Nasal Spray for Allergic Rhinitis
Jumpcan Pharmaceutical (SHA: 600566) announced a partnership with PrimeGenX Therapeutics Co., Ltd. granting Jumpcan exclusive...
Arctic Vision-Mdco Technology Merger Builds Ophthalmology Platform
Arctic Vision, a China‑based ophthalmology specialist, and Mdco Technology Co., Ltd. have agreed to integrate...
SanegeneBio Partners with Genentech on RNAi Therapy in $1.7B Deal
SanegeneBio, a Suzhou‑based RNA interference (RNAi) therapeutics developer, announced a global partnership with Genentech, a...
Zonsen Peplib Signs Eli Lilly Deal After Novartis Partnership
Zonsen Peplib Biotech Inc., a China‑based polypeptide lead compound developer, announced a collaboration with Eli...
WuXi Biologics Partners with Vertex on Trispecific T-Cell Engager for Autoimmune Diseases
WuXi Biologics (HKG: 2269) announced a partnership with Vertex Pharmaceuticals for an innovative trispecific T‑cell engager...
Zenshine Pharma Files for Hong Kong IPO with $357M Valuation
Nanjing Zenshine Pharmaceuticals Co., Ltd. submitted its initial public offering (IPO) filing to the Main...